Drug intelligence / Profile preview

Cyclophosphamide, Docetaxel, Epirubicin, Nab-paclitaxel, and Paclitaxel Combination Regimen

Development stage
Unknown
Lead developer
Takeda
Modality
Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration
Intravenous
01

Overview

The provided search results indicate that the exact 5-drug combination of cyclophosphamide, docetaxel, epirubicin, nab-paclitaxel, and paclitaxel is not a standard, single regimen used together. Instead, these drugs are commonly used in various two- or three-drug combinations, primarily for breast cancer treatment. Examples include: * **Docetaxel and cyclophosphamide (TC)**: Used as adjuvant therapy for breast cancer. * **Nab-paclitaxel followed by epirubicin/cyclophosphamide (EC)**: Used as neoadjuvant chemotherapy for triple-negative breast cancer. * **Nab-paclitaxel plus cyclophosphamide plus trastuzumab (AbraC-HER)**: Used as neoadjuvant treatment for HER2-positive breast cancer. These drugs are typically administered intravenously in cycles, with rest periods to allow recovery. They work by destroying rapidly dividing cells, such as cancer cells. Common side effects can include polyneuropathy, hematotoxicity, and allergic reactions, with severity varying between different combinations.

02

Targets

TUBB (Tubulin (alpha and beta subunits))TOP2A (DNA topoisomerase II)DNA

Beyond the preview

Go deeper on Cyclophosphamide, Docetaxel, Epirubicin, Nab-paclitaxel, and Paclitaxel Combination Regimen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cyclophosphamide, Docetaxel, Epirubicin, Nab-paclitaxel, and Paclitaxel Combination Regimen.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call